Virus nomenclature below the species level: A standardized nomenclature for filovirus strains and variants rescued from cDNA | Научно-инновационный портал СФУ

Virus nomenclature below the species level: A standardized nomenclature for filovirus strains and variants rescued from cDNA

Тип публикации: статья из журнала

Год издания: 2014

Идентификатор DOI: 10.1007/s00705-013-1877-2

Ключевые слова: Animalia, Ebola virus, Marburgvirus, article, classification, Filoviridae, genetic reassortment, genetics, virus genome, Genome, Viral, Reassortant Viruses

Аннотация: Specific alterations (mutations, deletions, insertions) of virus genomes are crucial for the functional characterization of their regulatory elements and their expression products, as well as a prerequisite for the creation of attenuated viruses that could serve as vaccine candidates. Virus genome tailoring can be performed either by using traditionally cloned genomes as starting materials, followed by site-directed mutagenesis, or by de novo synthesis of modified virus genomes or parts thereof. A systematic nomenclature for such recombinant viruses is necessary to set them apart from wild-type and laboratory-adapted viruses, and to improve communication and collaborations among researchers who may want to use recombinant viruses or create novel viruses based on them. A large group of filovirus experts has recently proposed nomenclatures for natural and laboratory animal-adapted filoviruses that aim to simplify the retrieval of sequence data from electronic databases. Here, this work is extended to include nomenclature for filoviruses obtained in the laboratory via reverse genetics systems. The previously developed template for natural filovirus genetic variant naming, <virus name=""> (<strain>/)<isolation host-suffix="">/<country of="" sampling="">/<year of="" sampling="">/<genetic variant="" designation="">-<isolate designation="">, is retained, but we propose to adapt the type of information added to each field for cDNA clone-derived filoviruses. For instance, the full-length designation of an Ebola virus Kikwit variant rescued from a plasmid developed at the US Centers for Disease Control and Prevention could be akin to "Ebola virus H.sapiens-rec/COD/1995/Kikwit-abc1" (with the suffix "rec" identifying the recombinant nature of the virus and "abc1" being a placeholder for any meaningful isolate designator). Such a full-length designation should be used in databases and the methods section of publications. Shortened designations (such as "EBOV H.sap/COD/95/Kik-abc1") and abbreviations (such as "EBOV/Kik-abc1") could be used in the remainder of the text, depending on how critical it is to convey information contained in the full-length name. "EBOV" would suffice if only one EBOV strain/variant/isolate is addressed. © 2013 Springer-Verlag Wien (outside the USA).</isolate></genetic></year></country></isolation></strain></virus>

Ссылки на полный текст

Издание

Журнал: Archives of Virology

Выпуск журнала: Vol. 159, Is. 5

Номера страниц: 1229-1237

Авторы

  • Kuhn J.H. (Integrated Research Facility at Fort Detrick (IRF-Frederick), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, Frederi)
  • B?o Y. (Information Engineering Branch, National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, United States)
  • Bavari S. (United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, United States)
  • Becker S. (Institut f?r Virologie, Philipps-Universit?t Marburg, Marburg, Germany)
  • Bradfute S. (University of New Mexico, Albuquerque, NM, United States)
  • Brauburger K. (Department of Microbiology and National Emerging Infectious Diseases Laboratory, Boston University School of Medicine, Boston, MA, United States)
  • Rodney Brister J. (Information Engineering Branch, National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, United States)
  • Bukreyev A.A. (Department of Pathology and Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, United States)
  • Ca? Y. (Integrated Research Facility at Fort Detrick (IRF-Frederick), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, Frederick,)
  • Chandran K. (Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, United States)
  • Davey R.A. (Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX, United States)
  • Dolnik O. (Institut f?r Virologie, Philipps-Universit?t Marburg, Marburg, Germany)
  • Dye J.M. (United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, United States)
  • Enterlein S. (Integrated BioTherapeutics, Inc., Gaithersburg, MD, United States)
  • Gonzalez J.-P. (Health Department, Institut de Recherche pour le D?veloppement, Marseille, France, Metabiota, Inc., San Francisco, CA, United States)
  • Formenty P. (World Health Organization, Geneva, Switzerland)
  • Freiberg A.N. (Department of Pathology and Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, United States)
  • Hensley L.E. (Integrated Research Facility at Fort Detrick (IRF-Frederick), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, Fred)
  • Hoenen T. (Laboratory for Virology, Division of Intramural Research, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, United States)
  • Honko A.N. (United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, United States)
  • Ignatyev G.M. (Federal State Unitary Company Microgen Scientific Industrial Company for Immunobiological Medicines, Ministry of Health of the Russian Federation, Moscow, Russian Federation)
  • Jahrling P.B. (Integrated Research Facility at Fort Detrick (IRF-Frederick), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, Fre)
  • Johnson K.M. (K.M.)
  • Klenk H.-D. (Institut f?r Virologie, Philipps-Universit?t Marburg, Marburg, Germany)
  • Kobinger G. (Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada)
  • Lackemeyer M.G. (Integrated Research Facility at Fort Detrick (IRF-Frederick), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, F)
  • Leroy E.M. (Centre International de Recherches M?dicales de Franceville, Franceville, Gabon)
  • Lever M.S. (Biomedical Sciences Department, Dstl, Porton Down, Salisbury, Wiltshire, United Kingdom)
  • M?hlberger E. (Department of Microbiology and National Emerging Infectious Diseases Laboratory, Boston University School of Medicine, Boston, MA, United States)
  • Netesov S.V. (Novosibirsk State University, Novosibirsk, Novosibirsk Region, Russian Federation)
  • Olinger G.G. (United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, United States)
  • Palacios G. (United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, United States)
  • Patterson J.L. (Department of Virology and Immunology, Texas Biomedical Research Institute, San Antonio, TX, United States)
  • Paweska J.T. (Center for Emerging and Zoonotic Diseases, National Institute for Communicable Diseases of the National Health Laboratory Service, Sandringham-Johannesburg, Gauteng, South Africa)
  • Pitt L. (United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, United States)
  • Radoshitzky S.R. (United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, United States)
  • Ryabchikova E.I. (Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, Novosibirsk, Novosibirsk Region, Russian Federation)
  • Saphire E.O. (Department of Immunology and Microbial Science and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, United States)
  • Shestopalov A.M. (Novosibirsk State University, Novosibirsk, Novosibirsk Region, Russian Federation, State Research Center of Virology and Biotechnology Vector, Koltsovo, Novosibirsk Region, Russian Federation)
  • Sullivan N.J. (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States)
  • Swanepoel R. (Zoonoses Research Unit, University of Pretoria, Pretoria, South Africa)
  • Takada A. (Division of Global Epidemiology, Hokkaido University Research Center for Zoonosis Control, Sapporo, Japan)
  • Towner J.S. (Centers for Disease Control and Prevention (CDC), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens Pathology (DHCPP), Viral Special Pathogens Branch (VSPB), 1600 Clifton Road, Atl)
  • van der Groen G. (Prins Leopold Instituut voor Tropische Geneeskunde, Antwerp, Belgium)
  • Volchkov V.E. (Laboratoire des Filovirus, Inserm U758, Universit? de Lyon, UCB-Lyon-1, Ecole-Normale-Sup?rieure de Lyon, Lyon, France)
  • Volchkova V.A. (Laboratoire des Filovirus, Inserm U758, Universit? de Lyon, UCB-Lyon-1, Ecole-Normale-Sup?rieure de Lyon, Lyon, France)
  • Wahl-Jensen V. (Integrated Research Facility at Fort Detrick (IRF-Frederick), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, Fr)
  • Warren T.K. (United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, United States)
  • Warfield K.L. (Integrated BioTherapeutics, Inc., Gaithersburg, MD, United States)
  • Weidmann M. (Universit?tsmedizin G?ttingen, Abteilung Virologie, G?ttingen, Germany)
  • Nichol S.T. (Centers for Disease Control and Prevention (CDC), National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of High-Consequence Pathogens Pathology (DHCPP), Viral Special Pathogens Branch (VSPB), 1600 Clifton Road, Atl)
  • Kuhn J.H. (Integrated Research Facility at Fort Detrick (IRF-Frederick), Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), B-8200 Research Plaza, Fort Detrick, Frederi)

Вхождение в базы данных

  • Scopus (цитирований 56)

Информация о публикациях загружается с сайта службы поддержки публикационной активности СФУ. Сообщите, если заметили неточности.

Вы можете отметить интересные фрагменты текста, которые будут доступны по уникальной ссылке в адресной строке браузера.